Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia

Inclusion Criteria: * Written informed consent to participate * At least 18 years of age * Participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia * Part 1: For participants treated to a maximum of 6 months or intended to be treated with bempedoic acid/FDC under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the participant in the study at the discretion of the physician under no reimbursement conditions at enrollment * Part 2: For participants treated or intended to be treated with bempedoic acid/FDC under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the patient in the study under reimbursed conditions at enrollment * No contraindications exist according to the SmPC of bempedoic acid/ FDC * No concurrent participation in an interventional study (Simultaneous participation in other non-interventional studies is possible) * Life expectancy \> 1 -year Exclusion Criteria: * As this is a non-interventional study, no explicit exclusion criteria exist in order to avoid selection bias and to allow for documentation of routine clinical practice.